Thyroid neoplasms
Research activity includes advanced radioactive-iodine-refractory differentiated thyroid carcinoma and anaplastic thyroid carcinoma, with interest in therapies directed at TROP-2 and cabozantinib in thyroid cancer.
- Differentiated thyroid carcinoma
- Anaplastic thyroid carcinoma
- TROP-2-targeted therapy
- Biomarkers in thyroid cancer
The sponsor also supports work on predictive blood-based markers and treatment response assessment in advanced thyroid malignancies.
Digestive neuroendocrine carcinomas and high-grade disease
Clinical research focuses on neuroendocrine carcinomas of the digestive system and unknown primary origin, as well as G3 neuroendocrine tumours with aggressive biological behavior.
- Advanced neuroendocrine carcinoma
- G3 neuroendocrine tumours
- Digestive system origin
- Unknown primary neuroendocrine cancer
Therapeutic interest extends to tarlatamab and combination approaches in refractory high-grade disease.
Midgut neuroendocrine tumors
Supported studies address well-differentiated neuroendocrine tumors of midgut origin, with attention to disease control and reduction of treatment-related toxicity in somatostatin receptor-positive disease.
- Grade 1-2 midgut NETs
- Radioligand therapy
- Somatostatin receptor-targeted treatment
- Hematological toxicity
Research in this area includes 177Lu-DOTATATE and other approaches aimed at maintaining control in slowly progressive disease.
Neuroendocrine tumors of the lung and thymus
The sponsor is involved in studies for patients with well to moderately differentiated neuroendocrine tumors of the lung and thymus requiring systemic therapy.
- Lung neuroendocrine tumors
- Thymic neuroendocrine tumors
- Systemic therapy
- Progression-free survival
Therapeutic comparisons include 177Lu-edotreotide and everolimus in advanced disease.
Advanced treatment-resistant neuroendocrine oncology
Across its portfolio, the sponsor supports research in refractory and metastatic neuroendocrine cancers, including patients who are not eligible for standard first-line platinum-based chemotherapy.
- Metastatic neuroendocrine cancer
- Refractory disease
- Antibody-drug conjugates
- Targeted and radioligand therapies
Interest also extends to objective response and overall survival outcomes in difficult-to-treat neuroendocrine and thyroid malignancies.
